<DOC>
	<DOCNO>NCT00361075</DOCNO>
	<brief_summary>The postmenopausal state associate increase risk heart disease . Much increase risk may due loss estrogen ( main female hormone ) effect loss lipid ( blood fat ) . This loss estrogen often treat estrogen replacement therapy . Estrogen replacement therapy seem beneficial effect lipid level . The purpose research study understand 1 ) menopause affect lipid 2 ) hormone replacement therapy effect lipid metabolism postmenopausal woman .</brief_summary>
	<brief_title>Midlife Cholesterol Study</brief_title>
	<detailed_description>Women Metabolic Syndrome ( central obesity , insulin resistance , dyslipidemia ) especially high risk coronary heart disease ( CHD ) . The prevalence Metabolic Syndrome increase menopause may partially explain acceleration CHD menopause . Menopause associate increased central adiposity , insulin resistance , dyslipidemia ( hypertriglyceridemia , increase low density lipoprotein ( LDL ) , reduce high density lipoprotein ( HDL ) small dense LDL particle ) , increase thrombotic/inflammatory state , study investigate mechanisms mediate change . The objective propose project investigate emergence feature Metabolic Syndrome woman follow prospectively menopause determine feature reverse transdermal estrogen . We hypothesize increase central adiposity menopause major contributor increase prevalence Metabolic Syndrome menopause . This first prospective study investigate 1 ) effect menopause 2 ) estrogen replacement therapy ( ERT ) ( oral vs. transdermal ) feature Metabolic Syndrome . We determine increase central ( intraabdominal ) fat menopause associate change lipid , insulin resistance , adipocytokines , fibrinolytic/inflammatory marker . We determine change reverse transdermal ERT , compare oral ERT , pharmacologic effect liver .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Have demonstrate interest participate ERT trial Be premenopausal ( menstrual period previous three month ) prior start observational arm Prior start interventional arm ( ERT ) , woman must postmenopausal ( menstrual cycle past twelve month FSH &gt; 30 ) Be age 47 55 Not take form estrogen replacement Have intact uterus least one ovary normal screen mammogram 12 month prior start ERT Body mass index ( kg/m2 ) great 40 kg/m2 History diabetes mellitus fast &gt; 110 mg/dl screen Abnormal fast LDL triglyceride Use lipid lowering medication , betablockers , birth control pill Active liver disease ( recent history active hepatitis , jaundice , scleral icterus , and/or elevate liver function test History breast , endometrial ovarian cancer History thrombotic disorder ( past history pulmonary embolus deep venous thrombosis ) know history CAD</criteria>
	<gender>Female</gender>
	<minimum_age>47 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Perimenopause</keyword>
	<keyword>Abdominal adipose tissue</keyword>
	<keyword>Women 's health</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Lipid Metabolism</keyword>
</DOC>